Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma-Reference-Cited by-同舟云学术

Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

Published:2019-02-22 Issue:2 Volume:2 Page:e190035
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Whittington Melanie D.¹,McQueen R. Brett¹,Ollendorf Daniel A.²,Kumar Varun M.²,Chapman Richard H.²,Tice Jeffrey A.³,Pearson Steven D.²,Campbell Jonathan D.¹

Affiliation:

1. Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora

2. Institute for Clinical and Economic Review, Boston, Massachusetts

3. Department of Medicine, University of California, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/2/e190035/17298505/whittington_2019_oi_190004.pdf

Reference19 articles.

1. Guidelines for the management of diffuse large B-cell lymphoma.;Chaganti;Br J Haematol,2016

2. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.;Morton;Blood,2006

3. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.;Hamlin;Blood,2003

4. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin’s disease and non-Hodgkin’s lymphoma.;Mink;Oncologist,2001

5. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.;Vose;J Clin Oncol,2001

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain;Cancers;2024-07-30

3. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

4. Management of Relapsed Refractory Large B-Cell Non-Hodgkin Lymphoma;Advances in Oncology;2024-05

5. Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan;Future Oncology;2024-04-10